Why Protagonist Therapeutics Stock Is Tanking Today
Shares of Protagonist Therapeutics (NASDAQ: PTGX), a clinical-stage biotechnology company, are plummeting today. As of 2:26 p.m. EDT, the stock price has fallen 62.9% in response to news of a clinical hold from the FDA.
Protagonist Therapeutics is advancing an ambitious pipeline with five new drug candidates in clinical trials right now. Without any approved products to sell, the biotech lost $55 million in the first half of the year.
Image source: Getty Images.
Source Fool.com
